On Sept. 10, 2020, the NIH launched two of three adaptive Phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19.

Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, these trials will be conducted at more than 100 sites around the world and will involve patients in various clinical settings ﾗ those who have not been hospitalized, those currently hospitalized and those discharged after hospitalization for moderate to severe disease.